Abstract:A common feature of current biomedical science is inter-disciplinary research and collaboration. Translational research, the basis for translational medicine, integrates the basic sciences and clinical medicine with the aim of optimizing preventive measures and patient care, is at the cusp for expansion. Translational medicine, in short, is the process of turning appropriate biological discoveries into drugs and medical devices that can be used in the treatment of patients. Vigorous efforts have been made to link basic scientific research with clinical investigations. Notably, in the area of neurodegenerative disorders, more basic and clinical researchers as well as nations have joined forces to explore the interface between basic neurosciences and clinical neurology and psychology. Thus, the newly established journal of Translational Neurodegeneration will provide a perfect platform at the global level to share knowledge and experience of the latest research on the epidemiology, etiology, pathogenesis, diagnosis, management and prevention of neurodegenerative diseases. Indeed, the prevalence of neurodegenerative disorders, including Alzheimer's (AD) and Parkinson's (PD), has increased significantly as global populations age. Specifically, the number of cases of dementia in the developed world is projected to rise from 13.5 million in 2000 to 21.2 million in 2025, and to 36.7 million in 2050[1]. Currently, the number of deaths caused by AD is only next to the number of deaths caused by stroke. As the prevalence of AD grows, so does the cost to a nation. For PD, the second most common neurodegenerative after AD, more than 4 million people suffer from this devastating worldwide and that will double in the next 25 years [2]. To date, PD is still an incurable progressive neurological disorder that seriously impairs the quality of life. The discovery and application of levodopa (L-dopa) is one of the best examples of translational research for neurodegenerative diseases. In 1910s, L-dopa was first isolated from seedlings of Vicia faba; and in 1938, L-dopa decarboxylase was discovered, which can produce dopamine (DA) from L-dopa. In 1959, was found enriched in the basal ganglia; and in 1960, a severe striatal deficit was demonstrated in PD patients. These major discoveries and a deepening understanding of the neurochemistry of and the neuropathology of PD led to the concept of DA replacement with L-dopa. In 1961, L-dopa was tried in PD patients by i.v. treatment. In 1967, oral administration of L-dopa was reported to produce dramatic improvements in PD patients with increasing amounts over long periods [3]. However, the main side effects of increasing L-dopa administration, i.e., dyskinesias and motor fluctuations, became apparent. This clinical finding confused doctors and patients, and a solution was needed. In 1970s, the key cause was found. L-dopa decarboxylase degraded L-dopa to in peripheral blood, which can not across the blood-brain barrier. These findings led to the first L-dopa combination, benserazide/L-dopa or carbidopa/L-dopa by adding a dopa decarboxylase inhibitor to treatment, which showed advantages in reducing side effects and gaining better symptom control [4]. Since then, PD researchers have attempted to overcome complications with such techniques as continuous L-dopa infusion and, most recently, long-acting L-dopa combinations. Substantial progress has been made in understanding the pathogenesis of neurodegenerative diseases, but we are still a long way from applying it to clinical application. Translational research will definitely help overcome the bottleneck and barriers in 1) identifing and validating biomarkers for early or pre-clinical diagnosis as well as clinical progression; 2) promoting the innovative clinical technologies, such as neuroimaging, stem cell technology and nanotechnology; and 3) developing the novel drug candidates; and more importantly, to gain a multitude of new ideas and contacts back to research. Thus, launching a journal in translational neurodegenerative is essential and timely. The latest research on the etiology, pathogenesis, potential diagnostic markers and treatment modalities of PD has been presented at the XIX World Congress on Parkinson's Diseases and Related Disorders. Almost 2500 distinguished scientists, clinicians and allied health experts gathered in Shanghai, China, December 11-14, 2011 to enhance collaboration in these important inter-disciplinary research areas. Organized by the Association of Parkinsonism and Related Disorders and the local host, the Department of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, the congress is the highest level of academic conferences in the field of PD and related disorders. Several speakers and attendees contributed review and original articles for the inaugural issue of Translational Neurodegeneration. Notably, the articles are interdisciplinary and focus on many current issues facing translational neuroscience research. Research of gene mutation, especially of alpha-synuclein, has provided important clues in understanding the pathogenesis of PD. In cell models, A53T of alpha-synuclein can increase macroautophagy, which has not yet been detected in patients. Yue Huang et al [5]aimed in their article Macroautophagy in sporadic and the genetic form of Parkinson's with the A53T α-synuclein mutation to confirm the above changes in brain tissue of PD patients. Interestingly, they couldn't find any evidence to support the conclusion that alpha-synuclein is removed by macroautophagy; and the results may be opposite to the previous reports. This is followed by a review, provided by Dr. Shu-Leong Ho's group, titled Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease [6]. It gave a brief insight into the role of mitochondrial dysfunction and oxidative stress in the converging pathogenic processes involved in PD and demonstrated that mitochondrial uncoupling proteins (UCPs) may play a vital role in protecting neurons from various pathogenic stresses including those associated with PD. UCPs would be another potential target for the treatment of these neurological disorders. Peter A. LeWitt discussed the wide role of norepinephrine (NE) in his review titled Norepinephrine: the next therapeutics frontier for Parkinson's disease [7]. NE may affect both the motor and non-motor functions, such as cognition, depression, circadian rhythms, and orthostatic hypotension. More importantly, drugs like β-adrenoceptor antagonist and α2-adrenergic receptor antagonists might help to ameliorate motor, cognitive, and affective features of PD, suggesting NE's potential role in the treatment of motor and non-motor symptoms of PD. Jon Stoessl introduced the latest progress in Neuroimaging in the early diagnosis of neurodegenerative diseases [8]. SPECT and PET technologies have been widely used to assess the pre-and post-synaptic abnormalities of transmission to differentiate PD from the Parkinson-plus syndromes. DTI (diffusion tensor imaging), fMRI, task-free fMRI and FDG-PET may also provide help in the differential diagnosis of degenerative dementias. The use of multimodal imaging, especially when combined with other biomarkers, showed increasing promise for the early diagnosis of neurodegenerative diseases. Translational research and knowledge of neurodegeneration are expanding at a fast pace. The potential to find causes, treatments and cures for many neurological and neurodegenerative are available to us. This congress and our journal highlight the opportunities for interdisciplinary and global collaborations. By offering a high-visibility forum for new insights and discussions of translational research in neurodegenerative diseases, Translational Neurodegeneration will promote the rapid conversion of basic research to clinical applications benefiting patients better and faster. The concept and spirit of translational research in the field of neurodegenerative disorders will spread through Translational Neurodegeneration and the authors. We thank the authors, referees, and Springer and BioMed Central, our publisher, for their help in making this journal and first issue possible. Special thanks also go to Ms. Robin Taylor from the University of Nebraska Medical Center; Drs. Jianqing Ding and Yuyan Tan, managing Editors of Translational Neurodegeneration; Rui Jin Hospital leaders, colleagues, team members and leaders of Shanghai Jiao Tong University School of Medicine, University of Nebraska Medical Center, Society for Neurology Chinese Medical Association and Chinese Society for Neuroscience, without whose help the success of this undertaking could not have been realized.

Abstract:Clinical and Translational MedicineVolume 12, Issue 6 e936 LETTER TO EDITOROpen Access Induced neural stem/progenitor cell-derived extracellular vesicles promote recovery post-stroke Ge Gao, Ge Gao Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorCongcong Li, Congcong Li Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorJie Zhu, Jie Zhu Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorShiyang Sheng, Shiyang Sheng Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorZhanping Liang, Zhanping Liang Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorShengyang Fu, Shengyang Fu Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiangyu Li, Xiangyu Li Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYiyan Sun, Yiyan Sun Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYi Wang, Yi Wang Translational Research Center, Shanghai Yangzhi Rehabilitation Hospital affiliated to Tongji University School of Medicine, Shanghai, China Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, ChinaSearch for more papers by this authorXuanran Feng, Xuanran Feng Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiaohuan Xia, Corresponding Author Xiaohuan Xia xiaohuan_xia1@163.com orcid.org/0000-0002-0287-6319 Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, China Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, China Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, China Correspondence Jialin C. Zheng and Xiaohuan Xia, Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China. Email: jialinzheng@tongji.edu.cn; xiaohuan_xia1@163.comSearch for more papers by this authorJialin C. Zheng, Corresponding Author Jialin C. Zheng jialinzheng@tongji.edu.cn Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, China Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, China Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, China Collaborative Innovation Center for Brain Science, Tongji University, Shanghai, China Correspondence Jialin C. Zheng and Xiaohuan Xia, Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China. Email: jialinzheng@tongji.edu.cn; xiaohuan_xia1@163.comSearch for more papers by this author Ge Gao, Ge Gao Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorCongcong Li, Congcong Li Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorJie Zhu, Jie Zhu Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorShiyang Sheng, Shiyang Sheng Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorZhanping Liang, Zhanping Liang Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorShengyang Fu, Shengyang Fu Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiangyu Li, Xiangyu Li Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYiyan Sun, Yiyan Sun Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYi Wang, Yi Wang Translational Research Center, Shanghai Yangzhi Rehabilitation Hospital affiliated to Tongji University School of Medicine, Shanghai, China Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, ChinaSearch for more papers by this authorXuanran Feng, Xuanran Feng Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiaohuan Xia, Corresponding Author Xiaohuan Xia xiaohuan_xia1@163.com orcid.org/0000-0002-0287-6319 Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, China Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, China Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, China Correspondence Jialin C. Zheng and Xiaohuan Xia, Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China. Email: jialinzheng@tongji.edu.cn; xiaohuan_xia1@163.comSearch for more papers by this authorJialin C. Zheng, Corresponding Author Jialin C. Zheng jialinzheng@tongji.edu.cn Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital affiliated to Tongji University School of Medicine, Shanghai, China Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, China Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, China Collaborative Innovation Center for Brain Science, Tongji University, Shanghai, China Correspondence Jialin C. Zheng and Xiaohuan Xia, Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China. Email: jialinzheng@tongji.edu.cn; xiaohuan_xia1@163.comSearch for more papers by this author First published: 22 June 2022 https://doi.org/10.1002/ctm2.936Citations: 1 Ge Gao, Congcong Li, and Jie Zhu contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat To the editor, Ischemic stroke (IS) is one of the leading causes of mortality and disability worldwide.1 Among various therapeutic strategies for IS, the application/administration of stem cell-derived extracellular vesicles (EVs), heterogeneous populations of small bilipid layer-enclosed vesicles, has emerged as a promising one.2, 3 The administration of EVs derived from stem cells obtain similar neuroprotective and neuroregenerative effects to stem cell transplantation post IS.3 More importantly, compared to cell-therapy, EV-based therapy is with low immunogenicity, more flexible administration options, no vascular obstructive effect, reduced risk of secondary microvascular thrombosis, and ability to surface and content modification.3 Although mesenchymal stromal cells (MSCs) are the most commonly used stem cells for EVs generation, studies have demonstrated that neural stem/progenitor cell (NPC)-derived EVs (NPC-EVs) have better effects in improving post-stroke recovery than MSC-derived EVs.4 However, the application of NPCs as EVs producers is struggled with many concerns including religious/ethical questions and problematic logistics of acquiring fetal tissues, which can be overcame by reprogramming somatic cells into induced NPCs (iNPCs).5 Our previous studies found that iNPC-EVs are with proliferation and cell survival promotion potential no less than NPC-EVs in vitro, indicating iNPC-EVs as eligible substitutes of NPC-EVs.6, 7 Herein, we compared the therapeutic effects of NPC-EVs and iNPC-EVs on a model of IS using transient middle cerebral artery occlusion (MCAO) mice. MCAO was validated by triphenyltetrazolium chloride staining (Figure S1). NPCs were isolated from brain tissues of embryonic day 13.5 mice. iNPCs were generated by direct reprogramming of astrocyte via transgene approach.5 EVs were isolated from NPC and iNPC culture medium via ultracentrifugation, and characterized by western blotting, NTA analyses, and transmission electron microscopy (Figure S2). Indocyanine green-labeled EVs were injected intravenously and could be observed in whole mouse body and mouse brains including brain 5 min after administration (Figure S3). Moreover, we analyzed the brain distribution of EVs after intravenously injecting Dil-labeled NPC- and iNPC-EVs. Dil signals were co-localized with the immunoreactivities of GFAP (Figure S4A), Iba1 (Figure S4B), and Tuj1 (Figure S4C), implying the uptake of NPC- and iNPC-EVs by glial and neuronal cells in mouse brains. We then assessed the sensorimotor functions of MCAO mice (Figure 1A). We examined the forelimb grip strength of the mice using hanging wire test, where both NPC- and iNPC-EV-injected MCAO mice significantly outperformed control MCAO animals (Figure 1B). The rotarod test also showed alleviation in both NPC- and iNPC-EVs injection groups, which outperformed the control MCAO groups (Figure 1C). Similarly, the adhesive removal test demonstrated significant reduction of the tape-remove times in both NPC- and iNPC-EVs injection groups versus MCAO controls (Figure 1E). Interestingly, only iNPC-EV-injected mice showed significantly shorter tape-contact times than MCAO controls (Figure 1D). Furthermore, we observed long-term improvements in cognitive function of iNPC-EV-injected MCAO mice, but not NPC-EV-injected ones, in the morris water maze test versus MCAO controls, including a significantly reduction in the latency to find the platform (Figure 1F,G), increased platform crossing numbers (Figure 1F,H), and more distance traveled/time spent in the target quadrant when the platform was removed (Figure 1I,J). No difference in swimming speed among different groups was observed, indicating similar gross motor skills across groups (Figure 1K). Overall, our results demonstrated that iNPC-EVs displayed comparable therapeutic effects as NPC-EVs in promoting sensorimotor function recovery and higher capacity in cognitive function improvement than NPC-EVs post MCAO. FIGURE 1Open in figure viewerPowerPoint Post-stroke administration of induced neural stem/progenitor cell (iNPC)-extracellular vesicles (EVs) improves neurological functions after middle cerebral artery occlusion (MCAO). Mice received intravenous injection of 300 μl EVs (0.5 μg/μl) or PBS 24 h after 30-min MCAO and at 2 days intervals on days 1–5 after stroke. (A) Experimental design. (A–E) Sensorimotor functions were assessed up to 14 d after MCAO or sham operation via hanging wire test (B), rotarod test (C), and adhesive removal test (D and E). (F–K) Long-term cognitive functions were evaluated in the Morris water maze. (F) Representative images of the swim paths of mice in each group. The escape times (G, learning), the time spent (H)/distance traveled (I)/platform crossing numbers (J) in the target quadrant (memory), and the swim speed (K) were recorded. n = 9–13/group. Error bars denote s.d.. *p < .05, **p < .01, ***p < .001, and ****p < .0001. ns denotes non-significance. The statistical difference among groups was assessed with the parametric one-way the analysis of variance (ANOVA) with post hoc Bonferroni test. Next, we examined the effects of both NPC- and iNPC-EVs on the histopathological changes post MCAO. Both EVs increased the proportions of Sox2+ and Ki67+ cells in the hippocampus (Figure 2A), peri-infarct cortex (Figure 2B), and sub-ventricular zone (SVZ) (Figure 2C) of EV-injected MCAO mice versus that of control MCAO mice, indicating a positive role of EVs on the expansion of NPC pool and the proliferation of NPCs post MCAO. Both NPC- and iNPC-EVs restored the loss of neurons in the hippocampus (Figure 2D), cortex (Figure 2E), and SVZ (Figure 2F) of MCAO mouse brains, ascertained by the significant elevation of proportions of NeuN+ and DCX+ cells. The significantly higher proportions of NeuN+ cells might also indicate the neuroprotection effects of EVs in the initial phase of post-stroke. Therefore, both EVs enhance neurogenesis post MCAO, and iNPC-EVs may be with higher efficacy in promoting NPC proliferation (Figure 2B) and neuroregeneration in the MCAO brain (Figure 2D–F). Besides, western blotting results indicated significant down-regulation and up-regulation of the expression levels of pro-inflammatory factor Cox2 and anti-inflammatory protein MRC1, respectively, in the hippocampal (Figure 3A) and peri-infarct cortical (Figure 3B) tissue lysates of EV-injected MCAO mice, compared with that of control mice. EV-injected mice also showed a significant decline in the proportions of Iba1+ cells in the hippocampus (Figure 3C) and peri-infarct cortex (Figure 3D) versus control mice, suggesting comparable anti-inflammatory effects of both NPC- and iNPC-EVs post MCAO. Furthermore, the administration of EVs abrogated the MCAO-induced down-regulation of anti-apoptotic Bcl2 expression in the hippocampus (Figure 3E) and peri-infarct cortex (Figure 3F). The injection of iNPC-EVs but not NPC-EVs inhibited pro-apoptotic Casp3 and Casp8 expression in tested brain regions (Figure 3E,F). The TUNEL assay also showed anti-apoptotic effects of EVs in the MCAO mouse hippocampus, suggesting that both NPC- and iNPC-EVs promote cell survival in the MCAO mouse brain, and iNPC-EVs exhibited higher anti-apoptotic potential than NPC-EVs (Figure 3G,H). We also examined the levels of pro-inflammatory cytokines TNF-α and IL-6 in mouse sera 3 days after intravenous injection of EVs via ELISA assay. No significant difference has been observed among PBS-, NPC-EV-, and iNPC-EV-injected mice and control ones, suggesting minor effects of EVs on peripheral immune system (Figure S5). It is worth-noting that the long-term therapeutic outcomes of NPC- and iNPC-EVs post IS may be mediated, partially at least, by the shot-term therapeutic effects of EVs, which needs to be determined in the future study. Thus, both behavioral test and histological/molecular studies suggested outstanding therapeutic potential of both NPC- and iNPC-EVs in treating IS without significant adverse effect. Since promising results have been reported for the clinical safety of clinical-grade EVs,8 the production and clinical safety of clinical-grade iNPC-EVs are required to be investigated in our future study. FIGURE 2Open in figure viewerPowerPoint Post-stroke administration of induced neural stem/progenitor cell (iNPC)-extracellular vesicles (EVs) improves neurogenesis, inhibits neuroinflammation and represses apoptosis. Focal cerebral ischemic brains treated with or without EVs, and their sham controls were collected on day 28 after middle cerebral artery occlusion (MCAO). (A–C) Representative confocal microscopy images of Sox2 (green) and Ki67 (green) in the hippocampus (A), peri-infarct cortex (B) and sub-ventricular zone (SVZ) (C). Proportions of cells with Sox2 and Ki67 immunoreactivities in each group were given on the right panel (n = 4). (D–F) Representative confocal microscopy images of DCX (green) and NeuN (red) in the hippocampus (D), peri-infarct cortex (E), and SVZ (F). Proportions of cells with DCX and NeuN immunoreactivities in each group were given on the right panel (n = 4). Scale bar: 100 μm. Error bars denote s.d.. *p < .05, **p < .01, ***p < .001 and ****p < .0001. ns denotes non-significance. The statistical difference among groups was assessed with the parametric one-way ANOVA with post hoc Bonferroni test FIGURE 3Open in figure viewerPowerPoint Post-stroke administration of induced neural stem/progenitor cell (iNPC)-extracellular vesicles (EVs) inhibits neuroinflammation. Focal cerebral ischemic brains treated with or without EVs, and their sham controls were collected on day 28 after middle cerebral artery occlusion (MCAO). (A and B) Representative blot (left) and quantification (right) of Cox2 and MRC1 protein expression levels in the hippocampus (A) and the peri-infarct cortex (B) (n = 3). (C and D) Representative confocal microscopy images of Iba1 immunostaining (green) in the hippocampus (C) and the peri-infarct cortex (D). Proportions of cells with Iba1 immunoreactivities were given on the right panel (n = 4). (E and F) Transcript levels of Casp3, Casp8 and Bcl2 in the hippocampus (E) and the peri-infarct cortex (F) were determined by quantitative reverse transcription polymerase chain reaction (RT-qPCR) analyses (n = 4). (G and H) Representative confocal microscopy images of TUNEL (red) staining in the hippocampus (G) and the peri-infarct cortex (H). Proportions of TUNEL positive cells were given on the right panel (n = 4). RT-qPCR data were normalized to Gapdh and presented as fold changes compared with sham control groups. Western blotting data were normalized to β-actin. Scale bar: 100 μm. Error bars denote s.d.. *p < .05, **p < .01, ***p < .001, and ****p < .0001. ns denotes non-significance. The statistical difference among groups was assessed with the parametric one-way ANOVA with post hoc Bonferroni test We then carried out preliminary studies to identify the potential mechanisms underlying the iNPC-EV-mediated recovery post MCAO. Since our proteomic analysis has implied enrichment of growth factor domains in iNPC-EVs,6 we examined the protein levels of multiple growth factors that are commonly expressed in the brain cells in EVs. Western blotting results detected EGF, FGF2, and IGF2 in both EVs, and iNPC-EVs contains higher levels of growth factors than NPC-EVs (Figure S6). Both EVs activated MEK-ERK pathway, but not PI3K-AKT pathway, in both hippocampal and cortical tissues, ascertained by the up-regulation of MEK and ERK phosphorylation (Figure S7). Moreover, iNPC-EVs are with stronger promoting effects on the activities of MEK-ERK pathway than NPC-EVs (Figure S7). EV-enhanced phosphorylation of ERK was further confirmed by immunohistochemistry, which displayed a significant increase of proportions of p-ERK+ cells in both NPC- and iNPC-EV treatment groups versus PBS controls (Figure S8). Given the important roles of MEK-ERK signaling in the neurogenesis, inflammation, and apoptosis,9, 10 our preliminary results implied that EVs achieve their therapeutic effects via modulating MEK-ERK signaling activities, and explained the potential mechanisms for the greater therapeutic effects of iNPC-EVs. In summary, iNPC-EVs are with therapeutic effects no less than NPC-EVs, suggesting iNPC-EVs as an outstanding succedaneum of NPC-EVs in treating IS. More importantly, since multiple histopathological features (e.g., neuroinflammation and neuronal damage/degeneration) are shared in neurological disorders, iNPC-EVs may also achieve therapeutic effects on treating acute brain injury like traumatic brain injury and chronic neurodegenerative diseases, which is under investigation. ACKNOWLEDGEMENTS We acknowledge Dr. Xinrui Qi, Jie Zhu, and Yanyan Zhang for the valuable comments for our study. This work was supported in part by research grants from the National Natural Science Foundation of China (grant numbers: 91949204, 81830037, 81971145 and 81901333). CONFLICT OF INTEREST The authors declare no competing commercial or financial interests. Supporting Information Filename Description ctm2936-sup-0001-SuppMat.docx2.4 MB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020; 141(9): e139- e596. 2Xia X, Wang Yi, Huang Y, Zhang H, Lu H, Zheng JC. Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents. Prog Neurobiol. 2019; 183:101694. 3Chen J, Chopp M. Exosome therapy for stroke. Stroke. 2018; 49(5): 1083- 1090. 4Webb RL, Kaiser EE, Scoville SL, et al. Human neural stem cell extracellular vesicles improve tissue and functional recovery in the murine thromboembolic stroke model. Transl Stroke Res. 2018; 9(5): 530- 539. 5Ma K, Deng X, Xia X, et al. Direct conversion of mouse astrocytes into neural progenitor cells and specific lineages of neurons. Transl Neurodegener. 2018; 7: 29. 6Ma Y, Wang K, Pan J, et al. Induced neural progenitor cells abundantly secrete extracellular vesicles and promote the proliferation of neural progenitors via extracellular signal-regulated kinase pathways. Neurobiol Dis. 2018; 124: 322- 334. 7Ma Y, Xu X, Li C, et al. Induced neural progenitor cell-derived extracellular vesicles promote neural progenitor cell survival via extracellular signal-regulated kinase pathway. CNS Neurosci Ther. 2021; 27: 1605- 1609. 8Shi M-M, Yang Q-Y, Monsel A, et al. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracell Vesicles. 2021; 10(10):e12134. 9Sun Y, Liu W-Z, Liu T, Feng X, Yang N, Zhou H-F. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 2015; 35(6): 600- 604. 10Kim EK, Choi E-J. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015; 89(6): 867- 882. Citing Literature Volume12, Issue6June 2022e936 FiguresReferencesRelatedInformation

Translational Neurodegeneration in the era of fast growing international brain research

The 2020 Yearbook of Neurorestoratology

Top ten discoveries of the year: Neurodegeneration

The 2021 yearbook of Neurorestoratology

The 2023 Yearbook of Neurorestoratology

Translational Neuroscience: Toward New Therapies

Translational Neurodegeneration, a platform to share knowledge and experience in translational study of neurodegenerative diseases

Join us on an amazing journey towards next‐generation treatments for CNS disorders: Launch of Neuroprotection, a new high‐quality journal in translational neuroscience

The 2022 Yearbook of Neurorestoratology

2016 yearbook of neurorestoratology

Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry

The Century of Neuroscience

Induced neural stem/progenitor cell‐derived extracellular vesicles promote recovery post‐stroke

Editorial: Understanding the Heterogeneity and Spatial Brain Environment of Neurodegenerative Diseases Through Conventional and Future Methods

New Focuses Of Clinical And Translational Medicine In 2020

Automatic Theranostics for Long-Term Neurorehabilitation after Stroke

2017 Yearbook of Neurorestoratology

Neurodevelopmental disorders: 2024 update

Bibliometric Analysis of Research on Neurodegenerative Diseases and Single-Cell RNA Sequencing: Opportunities and Challenges